Find clinical trials for COVID-19 in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections

Communicable Diseases

Coronavirus Infections

Pneumonia

Post-Acute COVID-19 Syndrome

Syndrome

Human Influenza

COVID-19 trials near London, England, GBR:

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled -...

Enrolling

Covid19

Pneumonia

Drug: Ruxolitinib

Drug: Fostamatinib

Phase 1, Phase 2

Imperial College London

London, United Kingdom

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PROTECT-V)

COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to pre-...

Enrolling

Covid19

Drug: Sotrovimab

Drug: Placebo

Phase 2, Phase 3

NHS Foundation Trust

London, United Kingdom and 44 other locations

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infe...

Active, not recruiting

COVID-19

Biological: Placebo

Biological: Remdesivir

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)

London, United Kingdom and 123 other locations

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immu-...

Active, not recruiting

Covid19

SARS-CoV-2 Infection

Biological: 5x10^9 vp AZD1222

Biological: 1x10^9 vp AZD1222

Phase 1

Imperial College London

London, United Kingdom

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its...

Active, not recruiting

COVID-19

Biological: mRNA-1273.222

Biological: mRNA-1283.222

Phase 3

Moderna

London, United Kingdom and 217 other locations

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...

Active, not recruiting

COVID-19, SARS-CoV-2

Biological: AZD3152 (Parent study Main Cohort)

Biological: AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152

Phase 2, Phase 3

AstraZeneca

London, United Kingdom and 214 other locations

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19 (LUNAR)

prioritized to receive early treatment for COVID-19 as they are at high risk of disease progression, and because of their potentia...

Enrolling

COVID-19

Drug: Sotrovimab

Phase 4

GlaxoSmithKline (GSK)

London, United Kingdom and 6 other locations

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need t...

Active, not recruiting

COVID-19

SARS CoV 2 Infection

Drug: Bemnifosbuvir (BEM)

Drug: Placebo

Phase 3

Atea Pharmaceuticals

London, Greater London, United Kingdom and 263 other locations

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years (COVID-19)

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting

COVID-19

Other: Placebo

Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)

Phase 2, Phase 3

Novavax

London, United Kingdom and 94 other locations

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity an...

Active, not recruiting

SARS-CoV-2 Infection

Drug: Intramuscular injection

Biological: Intramuscular vaccine

Phase 2, Phase 3

Medicago

London, United Kingdom and 90 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for COVID-19 in .css-epvm6{white-space:nowrap;}London, England

Related conditions:

COVID-19 trials near London, England, GBR:

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PROTECT-V)

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19 (LUNAR)

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years (COVID-19)

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Find clinical trials for COVID-19 in London, England